Are You Thinking About Investing In Grifols?

Shares of Grifols have moved 12.4% today, and are now trading at a price of $8.2. In contrast, the S&P 500 index saw a 1.1% change and the Dow Industrial Average posted a 1.9% performance. Today's trading volume is 2,131,964 compared to the stock's average volume of 1,359,420.

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. Based in Barcelona, the company has 27,584 full time employees and a market cap of $6,727,078,912.

The company is now trading -29.96% away from its average analyst target price of $11.7 per share. The 2 analysts following the stock have set target prices ranging from $10.4 to $13.01, and on average give Grifols a rating of hold.

Over the last year, GRFS shares have gone down by -39.1%, which represents a difference of -23.6% when compared to the S&P 500. The stock's 52 week high is $13.34 per share and its 52 week low is $5.71. With its gross margins declining an average -4.4% over the last four years, Grifols may not have a strong enough business to reverse this trend.

If you would like a free fundamental analysis of Grifols and other stocks that interest you, subscribe to our free newsletter!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.